The bone morphogenetic protein receptor II (BMPRII) signaling pathway is impaired in pulmonary arterial hypertension and mutations in the BMPR2 gene have been observed in both heritable and idiopathic pulmonary arterial hypertension. However, all BMPR2 mutation carriers do not develop pulmonary arterial hypertension, and inflammation could trigger the development of the disease in BMPR2 mutation carriers. Circulating levels and/or lung tissue expression of cytokines such as tumor necrosis factor-a or interleukin-18 are elevated in patients with pulmonary arterial hypertension and could be involved in the pathogenesis of pulmonary arterial hypertension. We consequently hypothesized that cytokines could trigger endothelial dysfunction in addition to impaired BMPRII signaling. Our aim was to determine whether impairment of BMPRII signaling might affect endothelium barrier function and adhesiveness to monocytes, in response to cytokines. BMPR2 was silenced in human lung microvascular endothelial cells (HLMVECs) using lentiviral vectors encoding microRNA-based hairpins. Effects of tumor necrosis factor-a and interleukin-18 on HLMVEC adhesiveness to the human monocyte cell line THP-1, adhesion molecule expression, endothelial barrier function and activation of P38MAPK were investigated in vitro. Stable BMPR2 silencing in HLMVECs resulted in impaired endothelial barrier function and constitutive activation of P38MAPK. Adhesiveness of BMPR2-silenced HLMVECs to THP-1 cells was enhanced by tumor necrosis factor-a and interleukin-18 through ICAM-1 adhesion molecule. Interestingly, tumor necrosis factor-a induced activation of P38MAPK and disrupted endothelial barrier function in BMPR2-silenced HLMVECs. Altogether, our findings showed that stable BMPR2 silencing resulted in impaired endothelial barrier function and activation of P38MAPK in HLMVECs. In BMPR2silenced HLMVECs, cytokines enhanced adhesiveness capacities, activation of P38MAPK and impaired endothelial barrier function suggesting that cytokines could trigger the development of pulmonary arterial hypertension in a context of impaired BMPRII signaling pathway.
Introduction
Pulmonary arterial hypertension (PAH) is a severe and lifethreatening disease resulting in right heart failure and need for lung transplantation in many patients. Despite the recent development of several specific therapies for PAH, there is still no cure and the prognosis of the disease remains poor. 1 Current PAH-specific therapies mainly substitute pulmonary arterial endothelium-derived vasodilatory mediators, but do not reverse pulmonary vascular remodeling characterized by endothelium dysfunction, loss of pre-capillary pulmonary arteries and proliferation of pulmonary vascular cells resulting in obstruction of the vessel lumen. Among patients harboring a familial form of PAH, 70% carry an autosomal dominant mutation resulting in haploinsufficiency or loss-of-function of bone morphogenetic protein receptor II (BMPRII). BMPR2 gene mutations are also present in 20% of sporadic cases of idiopathic PAH 2 ; mutations in other receptors of the transforming growth factor (TGF-) family such as activin receptor-like kinase-type 1 3 and endoglin, 4 and affecting BMP signaling including SMAD9, 5 caveolin-1 6 and potassium channel subfamily K member 3 (KCNK3) 7 have been also identified in patients with PAH. However, BMPR2 mutation displays a low penetrance since only 20% of the BMPR2 mutation carriers develop clinical symptoms of PAH. In addition, this low penetrance suggests that BMPR2 mutation carriers may harbor enhanced susceptibility to an inflammatory insult, for instance. 8 Endothelium dysfunction plays a major role in the initiation and the progression of PAH and is associated with impaired BMP signaling as illustrated by decreased pulmonary arterial endothelial cells (PAECs) survival in response to injury, 9 impaired adhesion and migration, 10, 11 enhanced adhesiveness for monocytes in response to inflammatory mediators 12 and disordered angiogenesis. 13 Reduced expression of BMPRII results in impaired canonical BMP signaling including SMAD1/5/8 and Id proteins as well as in the implementation of compensatory alternative pathways including P38MAPK pathway. [14] [15] [16] [17] Accordingly, inflammatory mediators may contribute to P38MAPK activation in a context of impaired BMPRII function. 18 Considering the potential role of inflammatory cytokines and chemokines including IL1, 19 IL6, 20 IL8, 21 CCL2, 22 CXCL10, 23 CCL5 24, 25 and fraktalkine 26 in PAH and the recent demonstration of IL6 production by PAECs from BMPR2 mutation carriers in response to inflammatory mediators, 12 we hypothesized that cytokines could negatively affect the endothelial function in a context of impaired BMPRII signaling pathway.
Interestingly, interleukin-18 (IL18), a pro-inflammatory cytokine, implicated in the pathogenesis of atherosclerotic disease, 27 may display adverse effects on endothelium function by inducing apoptosis and increasing permeability of pulmonary microvascular endothelial cells (ECs), 28 increasing the expression of adhesion molecules in human dermal microvascular ECs 29 or inducing the expression of cytokines by ECs. 30 In addition, plasma levels of IL18 and its downstream chemokine, CXCL10, are increased in PAH patients, and medial pulmonary smooth muscle cells (SMCs) are a source of IL18 and its receptor, IL18R, in PAH patients. 31 Moreover, IL18 disruption has been recently shown to suppress hypoxia-induced PAH in mice. 32 Eventually, tumor necrosis factor-a (TNFa), another pro-inflammatory cytokine, is involved in the pathogenesis of PAH, 33 noteworthy by potentially contributing to endothelial dysfunction through P38MAPK. 34 Due to the limited access to native PAECs from PAH patients, we knocked down BMPR2 in human lung microvascular endothelial cells (HLMVECs) to obtain a stable BMPR2-silenced HLMVEC lineage, in which we investigated the effects of cytokines, including IL18 and TNFa, on endothelium function and on activation of the P38MAPK pathway.
Materials and methods

Tissue collection
Lung parenchyma was collected at the time of lung transplantation from patients with idiopathic PAH (n ¼ 8), from control subjects at the time of lobectomy or pneumonectomy for suspected localized lung tumor (n ¼ 8) and from an unused donor lung (n ¼ 1). After collection, lung tissue was immediately snap-frozen and stored at À 80 C until use. The study protocol was approved by the Institutional Ethics Committee of the University of Leuven and participants gave written informed consent. Demographic characteristics of patients and control subjects are briefly described in Table 1 .
Generation of lentiviral transfer plasmids and lentiviral vector production
Short interfering RNA (siRNA) sequence targeting human BMPR2 mRNA at positions 1920, 4277 and 7048 were developed using siSearch software (http://www.dharmacon. com/DesignCenter/DesignCenterPage.aspx). The number refers to the respective positions in the reference human BMPR2 mRNA (NM_001204.6) that are recognized by the siRNA. Based on this sequence, simian immunodeficiency virus (SIV)-based lentiviral vectors, gift of D. Ne`gre (ENS Lyon, France) and encoding microRNA 30 (miR30)based knockdown hairpins derived from the aforementioned siRNA, were generated to allow stable knockdown as previously described 35 (referred to as LV_miR_BMPR2_ 1920, LV_miR_BMPR2_4277 or LV_miR_BMPR2_7048, respectively), in addition to the control hairpins directed against the firefly luciferase (fLuc; LV_miR_fLuc). The transfer plasmid constructs, pGAE SIV SFFV-eGFP-P2Azeo-miRNA-HsBMPR2-WPRE and pGAE-SFFV-eGFP-P2A-zeo-miRNA-fLuc-WPRE contain a zeocin resistance cassette (zeo) driven from an SFFV (spleen focus forming virus) long terminal repeat promoter, followed by the respective miRs and the WPRE (woodchuck hepatitis virus posttranscriptional regulatory element). In addition, the constructs contain the cDNA for enhanced green fluorescent protein (eGFP) cassette as a reporter gene that allows monitoring of the transduced cells by flow cytometry. The eGFP reporter cDNA and the ZeoR cDNA are connected by a peptide2A sequence, which allows equimolar expression of both proteins from the same mRNA transcript. 36 All cloning steps were sequence verified. All lentiviral vector plasmids were designed and cloned at the Leuven Viral Vector Core and vector production was performed as previously described. 36 Briefly, vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped lentiviral vector particles were produced by triple transient polyethylenimine transfection in HEK293T cells using pMDG.2, which encodes the vesicular stomatitis virus glycoprotein envelope, pAD_SIV3þ, packaging plasmid and the transfer plasmid pGAE-SFFV-eGFP-P2A-zeo-miRNA-HsBMPR2-WPRE, to generate LV_miR_BMPR2_1920; _4277; _7048. In parallel, a control vector was produced with miR-based hairpins which target the mRNA of fLuc, resulting in LV_ miR_fLuc. The latter vector will be referred to as ''control'' throughout the text. Quality control tests for lentiviral vector production were conducted: transduction units/mL were assessed on 293T cells and p24 concentrations in pg/mL was determined by p24/p27 ELISA (Innotest HIV Ag mAb 480T, Innogenetics-Fujirebio).
Lentiviral vector transduction efficiency in HLMVEC
Stable BMPR2 knockdown and controls in HLMVEC were generated following lentiviral transduction. Briefly, HLMVECs were seeded in a T75 flask at a density of 200,000 cells. When HLMVECs were 40% confluent, cells were transduced with a serial dilution series of lentiviral vectors LV_miR_BMPR2_1920, LV_miR_BMPR2_4277, LV_miR_BMPR2_7048 and LV_miR_fLuc, as control. After 48 h, the medium was replaced with growth medium containing 200 mg/mL zeocin to select transduced cells. Transduction efficiency was evaluated by flow cytometry for eGFP expression. Transduction efficiencies in HLMVECs (% eGFP positive cells in the population) were similar for the different lentiviral vectors, LV_miR_BMPR2_7048, LV_miR_BMPR2_4277, LV_ miR_BMPR2_1920, for the respective dilutions ( Figure  S1A ). Expression of eGFP was slightly lower in HLMVECs transduced with the control vector (1/20: 90.7%; 1/40: 71.7%; 1/80: 62.2%). Consequently, we opted for a 1/40 dilution of the lentiviral vectors and determined the relative BMPR2 mRNA expression at this dilution. Relative BMPR2 mRNA expression was significantly lower (ANOVA, p<0.01) in HLMVECs transduced with LV_miR_BMPR2_4277 (7.5 Â 10 À4 AE 2.0 Â 10 À4 ) or LV_miR_BMPR2_1920 (2.5 Â 10 À4 AE 7.0 Â 10 À5 ) compared with LV_miR_BMPR2_7048 (2.2 Â 10 À3 AE 6.0 Â 10 À4 ) or control vector (2.5 Â À3 AE 7.0 Â 10 À5 ) ( Figure S1B ). The viability of HLMVECs transduced with the control vector was 95.3 AE 1.6% and with LV_miR_BMPR2_1920 was 97.0 AE 0.64%. The percentage of HLMVECs expressing eGFP were 78.8 AE 10.4% for the control vector and 89.2 AE 9.4% for LV_miR_BMPR2_1920 ( Figure S1C ). Consequently, LV_miR_BMPR2_1920 was chosen and named as BMPR2-KD.
Phenotyping of HLMVECs
Lentiviral vector-transduced HLMVECs were phenotyped by labeling cells with Dil-Ac-LDL and by immunofluorescence using antibodies against human CD31, VE-cadherin and von Willebrand factor (vWF), as previously described. 37 To quantify immunofluorescence staining, five images from non-overlapping fields on each slide were captured at 40 Â magnification. After having separated the different channels, red staining was measured using the ImageJ software and expressed as arbitrary units (AU). In addition, CD31 positive, viable HLMVECs were quantified by flow cytometry (FacsCanto II, Becton Dickinson) as described elsewhere. 12 
Cell adhesiveness assay
HLMVECs were seeded at a density of 12,500 cells/cm 2 on gelatin-coated 12 well-plates. Subconfluent HLMVECs were starved in starving medium for 24 h. The cells were stimulated with human recombinant TNFa (10 ng/mL) or IL18 (10 ng/mL) for 3 h. Human monocytic THP-1 cells were radio-labeled with 1 mCi [3H]-thymidine per 10 6 cells for 48 h and added (5 Â 10 5 per well) to the endothelial cell monolayer for 3 h at 37 C. Non-adherent cells were washed out. Radioactivity incorporated into monocytes in suspension and attached to the EC monolayer was quantified as previously described. 38 Data are expressed as percentage of adhering cells over cells initially added.
Assessment of HLMVEC permeability
HLMVECs were seeded onto 24-well Transwell Õ inserts (6.5 mm diameter, 0.4 mm pore size, Corning) at full confluence (100,000 cells/insert) to ensure formation of endothelial monolayer. After 24 h, HLMVECs were starved for 18 h. The HLMVEC monolayer was then stimulated with TNFa (10 ng/mL) or IL18 (10 ng/mL) for 4 h, washed twice with starvation medium, and 200 mL fluorescein isothiocyanate (FITC)-labeled bovine serum albumin (BSA; 0.1 mg/mL) in starvation medium was added to the upper chamber and 1 mL of starving medium was added to the lower chamber. Leakage of FITC-labeled BSA into the lower chamber was assessed by collecting 50 mL of sample from the lower chamber at baseline, after 30 min, 1, 2 and 4 h. Absorbance was measured at 450 nm using a FLUOstar Omega microplate reader (BMG Labtech). Concentrations of BSA were calculated and plotted vs. time; area under the curve (AUC) was calculated for each conditions.
Adhesion molecule expression
Subconfluent HLMVECs seeded onto fibronectin-coated chamber slides were starved for 18 h and further stimulated with 10 mg/mL TNFa or IL18 for 3 h at 37 C. HLMVECs were not permeabilized in order to detect adhesion molecules expressed only at the cell surface. ICAM-1 and VCAM-1 expression was detected by immunofluorescence using antibodies against ICAM-1 and VCAM-1 as previously described. 12 Quantification of immunofluorescence staining was performed as mentioned above.
BMPR2, IL18 and IL18R mRNA expression
Total RNA was extracted from pulmonary tissue and HLMVECs; mRNA expression levels of BMPR2, IL18, IL18 receptor (IL18R) and the housekeeping gene -actin were determined by qrtPCR as previously described. 12 
Western blotting
HLMVECs were grown to 90% confluence in six wellplates and starved in starving medium for 24 h and further stimulated with 10 mg/mL TNFa or IL18 for 1 h at 37 C. HLMVECs were washed twice in ice-cold phosphate-buffered saline, pH 7.4 and lysed for 30 min at 4 C in ice-cold RIPA buffer. The samples were centrifuged at 12,000 g for 15 min and protein concentrations were determined using the Bradford method. Proteins were separated by SDS-PAGE and transferred to polyvinylidenefluoride filters by electroblotting. Filters were blocked in Trisbuffered saline (TBS) containing 0.1% Tween-20 (TBS-Tween) and either 3% BSA or 5% nonfat dry milk for 1 h at room temperature (RT). Filters were incubated with primary antibodies overnight at 4 C in TBS-Tween containing either 3% BSA or 5% non-fat dry milk. Horseradish peroxidase-conjugated secondary antibodies were incubated in TBS-Tween for 1 h at RT and peroxidase staining was revealed by chemiluminescence, imaged and analyzed.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 7.03 (GraphPad Software Inc., La Jolla, California). Differences between groups were analyzed using Student's t-test, one-way or two-way ANOVA followed by a post-hoc Tukey test. All p-values are for two-sided tests. A value of p < 0.05 was considered statistically significant.
Continuous and normally distributed values are expressed as mean AE SD.
A detailed method section is available in the online supplemental data.
Results
Phenotyping of lentiviral vector-transduced HLMVECs
HLMVECs transduced with the control vector and BMPR2-silenced HLMVECs both expressed CD31 ( Fig. 1a and b ) and VE-cadherin ( Fig. 1c and d) at their surface, contained vWF in Weibel-Palade bodies ( Fig. 1e and f) and demonstrated Ac-LDL uptake ( Fig. 1g and h) . Immunofluorescence staining was further quantified and did not show any significant difference in the expression of specific endothelial markers, e.g. CD31, VE-cadherin, vWF and Ac-LDL uptake, between HLMVECs transduced with the control vector and BMPR2-silenced HLMVECs ( Figure S2 ).
BMPR2 silencing affects BMP signaling
Lentiviral vector transduction of HLMVECs with BMPR2-KD vector resulted in an 89% decrease in BMPR2 mRNA expression (p ¼ 0.0001; Fig. 2a ) and an 87% decrease in BMPRII protein expression (p ¼ 0.0001; Fig. 2b and c) , compared to cell transduced with control vector.
We further observed that in resting HLMVECs knocked down for BMPR2, SMAD1/5/8 phosphorylation (0.42 AE 0.13) was significantly lower (p ¼ 0.015) compared with resting control HLMVECs (0.81 AE 0.13; Fig. 3a and b) .
In addition, we found that silencing of BMPR2 in resting HLMVECs resulted in significantly higher phosphorylation levels of P38MAPK compared with resting control HLMVECs (0.78 AE 0.11 vs. 0.52 AE 0.07; p ¼ 0.003; Fig. 3c  and d ).
BMPR2 silencing negatively affects endothelium function
Next, we determined the effect of BMPR2 silencing on HLMVEC barrier function. We assessed the leakage of FITC-labeled BSA through the monolayer of HLMVECs transduced with either control or BMPR2-KD vectors over time. The increase in FITC-labeled BSA leakage through the monolayer of resting BMPR2-silenced HLMVECs was significantly higher compared to resting control HLMVECs over time (Fig. 4a) . After a 4-h period, BSA-FITC leakage was significantly higher (p ¼ 0.002) through BMPR2-silenced HLMVECs compared to control HLMVECs (2.07 AE 0.10 vs. 1.58 AE 0.16; Fig. 4b ).
Considering that activated endothelium may influence the attraction and infiltration of inflammatory cells, we investigated whether impaired BMPRII may affect the adhesiveness capacities of HLMVECs to monocytes. We did not observe any difference in the amount of adhering human monocytic cells (THP-1) between resting BMPR2-silenced HLMVECs and control HLMVECs (28.9 AE 3.4% vs. 28.4 AE 3.3%; Fig. 4c ). Accordingly, we did not find any differential expression in adhesion molecules ICAM-1 and VCAM-1 at the surface of resting BMPR2-silenced HLMVECs and control HLMVECs (Figs. 5a, d, g, j; 6c-f).
TNFa enhances P38MAPK activation in BMPR2-silenced HLMVECs
We found that expression of IL18 mRNA was 1.6-fold higher in pulmonary tissue from patients with IPAH compared with controls (p ¼ 0.02; Table 2 ). By contrast, expression of IL18 receptor mRNA was similar in pulmonary tissue from patients with IPAH compared with controls ( Table 2 ). Moreover, considering that the non-canonical P38MAPK pathway is involved in the inflammatory process mediated by cytokines such as TNFa, 33 we investigated whether IL18 and TNFa could further activate P38MAPK in BMPR2-silenced HLMVECs. We observed that IL18 did not induce any significant increase in P38MAPK activation both in control (0.52 AE 0.07 vs. 0.58 AE 0.15; p ¼ 0.39) and BMPR2-silenced HLMVECs (0.77 AE 011 vs. 0.85 AE 0.11; p ¼ 0.30), ( Fig. 7b and d) .
By contrast, TNFa induced a significant increase in P38MAPK phosphorylation in BMPR2-silenced HLMVECs (0.77 AE 0.11 vs. 1.01 AE 0.17; p ¼ 0.03), but not in control HLMVECs (0.52 AE 0.07 vs. 0.69 AE 0.23; p ¼ 0.10; Fig. 7a and c) . 
TNFa and IL18 enhance adhesiveness of BMPR2-silenced HLMVECs
Adhesiveness of BMPR2-silenced HLMVECs to THP-1 cells was significantly higher compared to that of control HLMVECs in the presence of IL18, (fold-increase: 1.18 AE 0.35 vs. 0.83 AE 0.06, p ¼ 0.03; Fig. 6b ) as well as in the presence of TNFa (fold-increase: 2.31 AE 0.75 vs. 1.35 AE 0.36, p ¼ 0.03; Fig. 6a ). In resting control HLMVECs or BMPR2-silenced HLMVECs, both ICAM-1 and VCAM-1 adhesion molecules were poorly expressed at the cell surface ( Fig. 5a, d, g, j) . TNFa significantly induced the expression of ICAM-1 at the surface of BMPR2-silenced HLMVECs (Figs. 5d, e and 6c) , but not at the surface of control HLMVECs (Figs. 5a, b and 6c ). IL18 did not induce the expression of ICAM-1 at the surface of both control and BMPR2-silenced HLMVECs (Figs. 5af and 6d) . By contrast, neither IL18 nor TNFa induced VCAM-1 expression at the surface of control and BMPR2-silenced HLMVECs (Figs. 5g-l and 6e, f) . These results suggest that TNFa-induced adhesiveness of BMPR2silenced HLMVECs could be attributed to enhanced ICAM-1 expression at their surface.
TNFa impairs endothelial barrier function in BMPR2-silenced HLMVECs
TNFa significantly reduced endothelium barrier function in both control and BMPR2-silenced HLMVECs (AUC: 2.29 AE 0.16 vs. 2.96 AE 0.20, p ¼ 0.049 and 3.29 AE 0.13 vs. 4.02 AE 0.13 ng/ml/h, p ¼ 0.031; Fig. 8a and c) . The TNFainduced loss of endothelium barrier function was similar in BMPR2-silenced and control HLMVECs (31 AE 9% vs. 23 AE 3% increase, p ¼ 0.42).
IL18 did not display any effect on endothelium barrier function both in control HLMVECs or BMPR2-silenced HLMVECs (AUC: 2.29 AE 0.16 vs. 2.24 AE 0.21 and 3.29 AE 0.13 vs. 3.48 AE 0.213 ng/ml/h; Fig. 8b and d) .
Discussion
In the present study, stable silencing of BMPR2 in HLMVECs resulted in reduced expression of BMPRII protein, decreased phosphorylation of SMAD1/5/8 proteins, loss of endothelium barrier function and activation of P38MAPK. Additionally, cytokines such as IL18 and TNFa induced adhesiveness of BMPR2-silenced HLMVECs to THP-1 monocytic cells, presumably through the adhesion molecule ICAM-1. Finally, TNFa-induced loss of endothelium barrier function in BMPR2-silenced HLMVECs was accompanied by P38MAPK activation. Altogether, these results suggest that in the absence of functional BMPRII signaling, cytokines such as IL18 and TNFa impair endothelial function, and concomitantly activate P38MAPK.
Effects of reduced BMPRII expression on pulmonary endothelial function
We found that stable silencing of BMPR2 in HLMVECs resulted in significantly decreased activation of the canonical downstream effectors of BMPRII, namely SMAD 1/5/8 proteins, similar to the decrease in SMAD protein activation observed in pulmonary arterial smooth muscle cells (PASMCs) from IPAH patients, 39 whereas transient BMPR2 silencing in HLMVECs or PASMCs did not alter SMAD1/5/8 protein phosphorylation. 14, 40 Interestingly, we observed that impairment of BMPRII signaling resulted in a loss of the endothelium barrier function. Accordingly, transient BMPR2 silencing resulted in increased permeability of human PAEC monolayer 41 ; in addition, an increase in pulmonary vascular reactivity has been observed in vivo in heterozygous BMPR2-deficient mice. 21, 42 These findings, together with the demonstration that SRC-dependent caveolar dysfunction may contribute to endothelial barrier dysfunction of PAECs from heterozygous null Bmpr2 þ/À mutant mice, 42 suggest that BMPRII plays a role in maintaining pulmonary endothelial barrier function. This is also consistent with a previous study whereby (i) BMP9 prevented lipopolysaccharide (LPS)-induced loss of endothelial barrier function of blood outgrowth EC monolayers from PAH patients with BMPR2 mutations and (ii) silencing of SMAD1/5/8 eliminated the capacity of BMP9 to enhance BMPRII expression in PAECs. 43 In addition, our current findings showing a concomitant loss of endothelial barrier function and decreased in SMAD protein activation in BMPR2-silenced HLMVECs confirms that canonical SMAD signaling is important in maintaining PAEC barrier function.
Surprisingly, BMPR2 silencing did not affect either HLMVEC adhesiveness properties to monocytic cells, or the expression of the adhesion molecules ICAM-1 and VCAM-1, whereas we previously found increased adhesiveness to monocytic cells concomitant with increased expression of ICAM-1 mRNA in HLMVECs isolated from BMPR2 mutation carriers PAH patients. 12 Discrepancies between HLMVECs from PAH patients with a BMPR2 mutation and BMPR2-silenced HLMVECs could be attributed to the use of siRNA to knockdown BMPR2. Whereas siRNA targets cellular mRNAs, mutations in patients are permanent alterations in the structure of the BMPR2 gene, which can be responsible for alterations in the trafficking of BMPRII to the cell surface. 44 In this respect, cysteine substitution in the ligand-binding or kinase domains results in reduced trafficking of mutant BMPRII to the cell surface, whereas variants carrying non-cysteine mutations in the kinase domain reach the cell surface, but fail in activating SMAD signaling pathway. 16 In parallel to a decrease in canonical SMADdependent BMPRII signaling pathway, we also observed that BMPR2 silencing resulted in increased activation of noncanonical SMAD-independent P38MAPK. Accordingly, increased phosphorylation of P38MAPK has been observed in hypoxia-and monocrotaline-induced PH in rats 45, 46 as well as in heterozygous BMPR2 deficient and mutant mice. 47 In addition, a loss of BMPRII in PASMCs results in activation of P38MAPK. 48 These results suggest that impaired BMPRII function may result in abnormal activation of alternative pathways such as the P38MAPK pathway.
BMPRII silencing and cytokine-induced endothelial dysfunction
Considering that effects of the cytokines IL18 or TNFa on the endothelium are potentially mediated by activation of P38MAPK, 49, 50 we consequently aimed to investigate whether IL18 and TNFa would (i) worsen endothelial dysfunction in addition to silencing of BMPRII and (ii) activate the non-canonical P38MAPK pathway.
Despite higher levels of IL18 mRNA observed in lung parenchyma from PAH patients, IL18 failed to further increase BMPRII silencing-induced P38MAPK activation in HLMVECs. By contrast, a synergic effect of TNFa and BMPR2 silencing on P38MAPK activation was observed in HLMVECs. These results indicate that TNFa, but not IL18, is able to potentiate the non-canonical SMAD-independent P38MAPK pathway, in a context of a loss of BMPRII in HLMVECs. Accordingly, loss of BMPRII induced prolonged phosphorylation of P38MAPK in response to TNFa in human PAECs. 18 In parallel, we observed that TNFa was able to potentiate the effects of a loss of BMPRII on the pulmonary endothelium barrier function. Endothelial barrier compromise is accompanied by an activation of the P38MAPK cascade in human PAECs; 51 in rats with hypoxia-induced PH, whereby BMPRII expression is reduced in the lungs, P38MAPK inhibitor reversed impaired endothelium-dependent relaxation in isolated pulmonary artery rings. 52 In addition, TNFa has been previously shown to induce endothelium permeability, concomitantly with an activation of P38MAPK; 49 treatment with TNFa resulted in increased permeability of BMPR2 knockdown human PAEC monolayers. 41 Although IL18 has been previously shown to induce vascular SMC proliferation and migration, 53, 54 and increase permeability of rat PMVEC monolayers, 28 we did not observe any additional effects of IL18 on endothelial barrier function in HLMVECs with a loss of BMPRII.
Whereas silencing of BMPRII had no effect on adhesiveness capacities of HLMVECs to monocytic cells, we observed that both IL18 and TNFa induced adhesion of BMPRII-silenced HLMVECs to THP-1. Accordingly, we previously found that CRP and TNFa increased adhesion of U937 monocytic cells to PMVECs isolated from PAH patients with a BMPR2 mutation. 12 Interestingly, lentiviral vector-mediated overexpression of BMPRII in HLMVECs has been recently shown to suppress LPS-induced neutrophil-endothelial adhesion. 55 TNFa-induced adhesiveness was mainly attributable to induced expression of ICAM-1. In addition, we have also observed that PMVECs isolated from PAH with a BMPR2 mutation displayed increased mRNA or protein expression of ICAM-1 in response to CRP and TNFa. 12 Inversely, when BMPRII is overexpressed in HLMVECs, LPS-induced ICAM-1 expression was dramatically reduced. 55 Eventually, our results are in line with the coincidence of BMPR2 heterozygosity with an inflammatory insult required to develop PAH. 56 
Limitations
Findings of the present study are mostly based on in vitro investigation, using ECs in which BMPR2 has been depleted. Silencing does not exactly reproduce the pathological situation of BMPR2 mutations and in vitro cellular assays only allow to investigate some mechanistic aspects of the consequences of a loss of BMPRII. However, considering that access to microvascular pulmonary ECs from PAH patients is extremely limited and only possible at the time of lung transplantation, silencing of BMPRII in HLMVECs is a rather fair alternative to overcome this challenge and further investigate the consequences of a loss of BMPRII on the pathobiology of pulmonary vascular cells.
Conclusion
In the present study, we observed that a loss of BMPRII in HLMVECs resulted in increased permeability and activation of p38 MAP kinase. In addition, we found that TNFa enhanced the effects of a loss of BMPRII on the pulmonary endothelium barrier function, and concomitantly on the activation of P38MAPK. Finally, TNFa-induced adhesion capacities of BMPR2-silenced HLMVECs were partially attributable to enhanced expression of ICAM-1 at the cell surface. Altogether, our results suggest that cytokines such as TNFa or IL18 could trigger the development of PAH, in addition to a loss of BMPRII.
